Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas

D. A. Clayman, S. M. Wolpert, D. O. Heros

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can be reduced if the BCNU is dissolved in dextrose in water. This article describes the results from 15 patients who received 42 courses of BCNU administered by supraophthalmic internal carotid, middle cerebral, or posterior cerebral artery infusions. None of the patients developed leukoencephalopathy as demonstrated by CT scanning. The average reduction in tumor volume was 36%, and the median survival time from the date of diagnosis was 73 weeks. These values are comparable to those of a previous group of 20 patients treated with infraophthalmic infusions, with the exception that none of the patients in the present group developed retinal damage.

Original languageEnglish (US)
Pages (from-to)767-771
Number of pages5
JournalAmerican Journal of Neuroradiology
Issue number4
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology


Dive into the research topics of 'Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas'. Together they form a unique fingerprint.

Cite this